Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839007 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
A Phase 2 study, sponsored by Nile Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00839007 is a Phase 2 study that has completed, run by Nile Therapeutics. The registered enrollment target is 77 participants.
The verdict
NCT00839007, a Phase 2 study, has completed, sponsored by Nile Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
Interventions
- DRUG CD-NP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839007
The ClinicalTrials.gov registry entry for NCT00839007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nile Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD-NP is the first listed.
NCT00839007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839007 about?
NCT00839007 is a clinical study titled "Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure". The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
What is the current status of trial NCT00839007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2009-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00839007?
The interventions under investigation include: CD-NP (DRUG).
Who is sponsoring clinical trial NCT00839007?
This trial is sponsored by Nile Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.